Dariusz Pawlak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4191823/publications.pdf

Version: 2024-02-01

155 papers	3,537 citations	172207 29 h-index	182168 51 g-index
158 all docs	158 docs citations	158 times ranked	4658 citing authors

#	Article	IF	Citations
1	The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats. Vaccine, 2022, 40, 1996-2002.	1.7	1
2	Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins. Journal of Clinical Medicine, 2022, 11, 2236.	1.0	1
3	Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patientsâ€"A Pilot Study. Journal of Clinical Medicine, 2022, 11, 2430.	1.0	5
4	Zebrafishâ€"An Optimal Model in Experimental Oncology. Molecules, 2022, 27, 4223.	1.7	6
5	Response of Human Glioblastoma Cells to Vitamin B12 Deficiency: A Study Using the Non-Toxic Cobalamin Antagonist. Biology, 2021, 10, 69.	1.3	4
6	Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 535-548.	2.5	18
7	The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-Î±2a and oral ribavirin. Journal of Psychiatry and Neuroscience, 2021, 46, E166-E175.	1.4	13
8	Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models. Pharmaceutics, 2021, 13, 359.	2.0	4
9	MO564CHRONIC EXPOSURE TO INDOXYL SULFATE CHANGES BONE PROPERTIES AND EXPRESSION OF SIRT2, SIRT3, AND SIRT7 GENES*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
10	Not Only Immune Escapeâ€"The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis. Cancers, 2021, 13, 2667.	1.7	7
11	Kynurenines as a Novel Target for the Treatment of Malignancies. Pharmaceuticals, 2021, 14, 606.	1.7	18
12	Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders. Cells, 2021, 10, 1603.	1.8	53
13	Crosstalk between Tryptophan Metabolism via Kynurenine Pathway and Carbohydrate Metabolism in the Context of Cardio-Metabolic Riskâ€"Review. Journal of Clinical Medicine, 2021, 10, 2484.	1.0	25
14	Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling. International Journal of Molecular Sciences, 2021, 22, 6563.	1.8	3
15	MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. Cancers, 2021, 13, 3203.	1.7	9
16	Preclinical Toxicity and Safety of MM-129â€"First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics, 2021, 13, 1222.	2.0	6
17	Serum PTH, PTH1R/ATF4 pathway, and the sRANKL/OPG system in bone as a new link between bone growth, cross-sectional geometry, and strength in young rats with experimental chronic kidney disease. Cytokine, 2021, 148, 155685.	1.4	2
18	Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. International Journal of Molecular Sciences, 2021, 22, 11149.	1.8	1

#	Article	IF	Citations
19	Monitoring of Cardiorespiratory Parameters in Ratsâ€"Validation Based on Pharmacological Stimulation. Pharmaceuticals, 2021, 14, 1223.	1.7	0
20	Kynurenine Pathway in Chronic Kidney Disease: Whatâ€™s Old, Whatâ€™s New, and Whatâ€™s Next?. International Journal of Tryptophan Research, 2020, 13, 117864692095488.	1.0	31
21	P0871THE IMPACT OF ENDOGENOUS PTH/PTH1R/ATF4 AXIS ON TRABECULAR AND CORTICAL BONE REMODELING AND BONE GROWTH OF YOUNG RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
22	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. International Journal of Molecular Sciences, 2020, 21, 5979.	1.8	6
23	The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1697-1711.	2.5	4
24	P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
25	P0874THE IMPACT OF CHRONIC EXPOSURE TO INDOXYL SULFATE ON BONE TURNOVER MARKERS, PTH, VITAMIN D3, AND BIOMECHANICAL AND DENSITOMETRIC PROPERTIES OF BONES IN RAT MODEL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
26	Neurobehavioral effects of uremic toxinâ€"indoxyl sulfate in the rat model. Scientific Reports, 2020, 10, 9483.	1.6	38
27	Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 51-61.	1.3	10
28	Oxidative Storm Induced by Tryptophan Metabolites: Missing Link between Atherosclerosis and Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-16.	1.9	16
29	INTRACELLULAR MECHANISMS OF TUMOR CELL IMMUNORESISTANCE. Acta Biochimica Polonica, 2020, 67, 143-148.	0.3	2
30	Important players in carcinogenesis as potential targets in cancer therapy: an update. Oncotarget, 2020, 11, 3078-3101.	0.8	2
31	Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165528.	1.8	4
32	The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents. Marine Drugs, 2019, 17, 539.	2.2	6
33	The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target. RSC Advances, 2019, 9, 3020-3029.	1.7	9
34	Survival of lymphocytes is not restricted by IDO-expressing fibroblast from rheumatoid arthritis patients. Immunopharmacology and Immunotoxicology, 2019, 41, 214-223.	1.1	3
35	FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
36	Effect of quinolinic acid â€" A uremic toxin from tryptophan metabolism â€" On hemostatic profile in rat and mouse thrombosis models. Advances in Medical Sciences, 2019, 64, 370-380.	0.9	5

#	Article	IF	Citations
37	The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats. Expert Opinion on Therapeutic Targets, 2019, 23, 353-364.	1.5	3
38	The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease. International Urology and Nephrology, 2019, 51, 491-502.	0.6	6
39	Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology, 2019, 100, 213-222.	1.3	295
40	An important pathway of apoptotic effect of nickel early released from orthodontic appliances â€“ Preliminary data. Pharmacological Reports, 2018, 70, 766-768.	1.5	2
41	RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. Cytokine, 2018, 106, 19-28.	1.4	12
42	Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease. International Urology and Nephrology, 2018, 50, 127-135.	0.6	19
43	Simultaneous use of erythropoietin and LFMâ€A13 as a new therapeutic approach for colorectal cancer. British Journal of Pharmacology, 2018, 175, 743-762.	2.7	16
44	Indoxyl Sulfate Promotes Arterial Thrombosis in Rat Model via Increased Levels of Complex TF/VII, PAI-1, Platelet Activation as Well as Decreased Contents of SIRT1 and SIRT3. Frontiers in Physiology, 2018, 9, 1623.	1.3	37
45	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. Bone, 2018, 113, 124-136.	1.4	10
46	Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-Î± 2a treatment. Psychoneuroendocrinology, 2018, 97, 1-7.	1.3	10
47	Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 1262.	1.8	5
48	Anticoagulant Properties of Poly(sodium 2-(acrylamido)-2-methylpropanesulfonate)-Based Di- and Triblock Polymers. Biomacromolecules, 2018, 19, 3104-3118.	2.6	16
49	New insight into organic anion transporters from the perspective of potentially important interactions and drugs toxicity. Journal of Physiology and Pharmacology, 2018, 69, .	1.1	5
50	The activation of the kynurenine pathway in a rat model with renovascular hypertension. Experimental Biology and Medicine, 2017, 242, 750-761.	1.1	25
51	The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. Bone, 2017, 105, 1-10.	1.4	23
52	Indoxyl sulfate â€“ the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrology, 2017, 18, 35.	0.8	78
53	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 836.	1.3	34
54	The Uremic Toxin Indoxyl Sulfate Accelerates Thrombotic Response after Vascular Injury in Animal Models. Toxins, 2017, 9, 229.	1.5	32

#	Article	IF	Citations
55	Immune suppression of IgG response against dairy proteins in major depression. BMC Psychiatry, 2017, 17, 268.	1.1	17
56	Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells. Current Pharmaceutical Biotechnology, 2017, 18, 127-137.	0.9	6
57	Aryl hydrocarbon receptor (AhR) and its endogenous agonist â€“ indoxyl sulfate in chronic kidney disease. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	16
58	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. PeerJ, 2017, 5, e3199.	0.9	7
59	The Toxicokinetic Profile of Dex40-GTMAC3â€"a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin. Frontiers in Pharmacology, 2016, 7, 60.	1.6	17
60	Serum metabolic fingerprinting after exposure of rats to quinolinic acid. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 175-182.	1.4	4
61	Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. Molecular and Cellular Biochemistry, 2016, 421, 1-18.	1.4	27
62	Methods of reducing the level of indoxyl sulfate â€“ one of the most potent protein-bound uremic toxins. Toxin Reviews, 2016, 35, 171-179.	1.5	4
63	Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice. Translational Research, 2016, 177, 98-112.e10.	2.2	20
64	Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-Î± and Ribavirin Treatment in Chronic Hepatitis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 169-175.	1.0	5
65	Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension. Heart, 2016, 102, 230-237.	1.2	28
66	The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite â€“ 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease. PLoS ONE, 2016, 11, e0163526.	1.1	23
67	Endocan â€" the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clinical Biochemistry, 2015, 48, 425-430.	0.8	33
68	A view at monoclonal antibodies in therapy of osteoporosis. Polish Annals of Medicine, 2015, 22, 149-154.	0.3	1
69	Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin. PLoS ONE, 2015, 10, e0119486.	1.1	28
70	oxLDL â€“ the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients. Thrombosis Research, 2014, 134, 711-716.	0.8	3
71	Effect of diabetes and oxidative stress on plasma CCL23 levels in patients with severe chronic kidney disease. Polish Archives of Internal Medicine, 2014, 124, 459-466.	0.3	8
72	Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio â€" Are they real oxidative stress markers in dialyzed patients?. Life Sciences, 2013, 92, 253-258.	2.0	25

#	Article	IF	Citations
73	YKL-40 in hemodialyzed patients with and without cardiovascular complications â€“ The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine, 2013, 62, 75-80.	1.4	11
74	Oxidized LDL to autoantibodies against oxLDL ratio â€“ The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis, 2012, 224, 252-257.	0.4	36
75	Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?. Translational Research, 2012, 160, 346-354.	2.2	25
76	Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis. Thrombosis Research, 2012, 129, 704-709.	0.8	12
77	The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: The effect of dialysis treatment. Diabetes Research and Clinical Practice, 2012, 98, 264-270.	1.1	11
78	Interleukin-21 in hemodialyzed patients: Association with the etiology of chronic kidney disease and the seropositivity against hepatitis C virus infection. Clinical Biochemistry, 2011, 44, 1416-1420.	0.8	6
79	Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clinical Biochemistry, 2011, 44, 838-843.	0.8	41
80	Hyperfibrinolysis, uPA/suPAR System, Kynurenines, and the Prevalence of Cardiovascular Disease in Patients With Chronic Renal Failure on Conservative Treatment. American Journal of the Medical Sciences, 2010, 339, 5-9.	0.4	284
81	3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1Î² (CCL4) in patients with chronic kidney disease. Clinical Biochemistry, 2010, 43, 1101-1106.	0.8	17
82	Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients. Clinical Biochemistry, 2010, 43, 1393-1398.	0.8	5
83	Systemic Levels of MMP2/TIMP2 and Cardiovascular Risk in CAPD Patients. Nephron Clinical Practice, 2010, 115, c251-c258.	2.3	18
84	Kynurenine and its metabolites in Alzheimer's disease patients. Advances in Medical Sciences, 2010, 55, 204-211.	0.9	215
85	Erythropoietin increases Epo and EpoR expression in DLD-1 cells. Polish Annals of Medicine, 2010, 17, 16-24.	0.3	2
86	Kynurenine pathway â€“ a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Advances in Medical Sciences, 2010, 55, 196-203.	0.9	75
87	Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thrombosis Research, 2010, 125, e40-e45.	0.8	25
88	Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas â€“ the new putative determinants of endothelial dysfunction in haemodialysis patients. Thrombosis Research, 2010, 126, 393-398.	0.8	5
89	Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells. Pharmacological Reports, 2010, 62, 926-937.	1.5	8
90	Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thrombosis Research, 2009, 124, 452-457.	0.8	31

#	Article	IF	Citations
91	Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thrombosis and Haemostasis, 2009, 102, 49-55.	1.8	41
92	The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis, 2009, 204, 309-314.	0.4	107
93	Kynurenine, quinolinic acidâ€"The new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis, 2009, 204, 561-566.	0.4	73
94	Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagulation and Fibrinolysis, 2009, 20, 590-594.	0.5	35
95	Kynurenine and Its Metabolitesâ€"Kynurenic Acid and Anthranilic Acid are Associated With Soluble Endothelial Adhesion Molecules and Oxidative Status in Patients With Chronic Kidney Disease. American Journal of the Medical Sciences, 2009, 338, 293-300.	0.4	31
96	Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Thrombosis Research, 2008, 121, 543-548.	0.8	16
97	Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. Thrombosis Research, 2008, 121, 787-791.	0.8	1
98	The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thrombosis Research, 2008, 122, 328-335.	0.8	25
99	Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thrombosis Research, 2008, 123, 166-170.	0.8	11
100	Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine, 2008, 43, 98-101.	1.4	34
101	The concentration of kynurenine in rat model of asthma.. Folia Histochemica Et Cytobiologica, 2008, 46, 199-203.	0.6	13
102	Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxidative Stress and Inflammation in Hemodialyzed Patients. American Journal of Nephrology, 2007, 27, 221-225.	1.4	5
103	Erythropoietin Therapy Decreased Tissue Factor, Its Pathway Inhibitor, and Oxidative Stress in Peritoneal Dialysis Patients with Diabetes. Nephron Clinical Practice, 2007, 107, c20-c25.	2.3	3
104	Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagulation and Fibrinolysis, 2007, 18, 467-471.	0.5	9
105	Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thrombosis Research, 2007, 119, 475-480.	0.8	15
106	Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thrombosis Research, 2007, 120, 871-876.	0.8	22
107	Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thrombosis Research, 2007, 120, 797-803.	0.8	18
108	Chronic viral hepatitis and iron affect the plasma levels of LIGHTâ€"a new member of the TNF superfamily in uraemic haemodialyzed patients. Cytokine, 2007, 39, 201-206.	1.4	2

#	Article	IF	Citations
109	Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis, 2007, 190, 199-204.	0.4	51
110	Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clinical Biochemistry, 2007, 40, 81-85.	0.8	36
111	LIGHTâ€"A new member of the TNF superfamily in the plasma, dialysate and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis. Clinical Biochemistry, 2007, 40, 1240-1244.	0.8	0
112	Carotid atherosclerosis is associated with enhanced Î²-chemokine levels in patients on continuous ambulatory peritoneal dialysis. Atherosclerosis, 2006, 186, 146-151.	0.4	19
113	Inflammation but not oxidative stress is associated with Î²-chemokine levels and prevalence of cardiovascular disease in uraemic patients. Cytokine, 2006, 35, 258-262.	1.4	15
114	Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thrombosis Research, 2006, 117, 517-522.	0.8	24
115	The Effect of Endurance Training on Regional Serotonin Metabolism in the Brain During Early Stage of Detraining Period in the Female Rat. Cellular and Molecular Neurobiology, 2006, 26, 1325-1340.	1.7	26
116	Long-Term Erythropoietin Therapy Decreases CC-Chemokine Levels and Intima-Media Thickness in Hemodialyzed Patients. American Journal of Nephrology, 2006, 26, 497-502.	1.4	9
117	Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. Medical Science Monitor, 2006, 12, CR181-5.	0.5	13
118	Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clinical Biochemistry, 2005, 38, 700-705.	0.8	50
119	Anthranilic Acidâ€"uraemic Toxin Damaged Red Cellâ€™s Membrane. International Urology and Nephrology, 2005, 37, 621-627.	0.6	8
120	Circulating Î²-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients â€" Role of oxidative stress. Cytokine, 2005, 31, 18-24.	1.4	18
121	Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients. Thrombosis and Haemostasis, 2004, 92, 646-653.	1.8	17
122	Oxidative Stress Influences CC-Chemokine Levels in Hemodialyzed Patients. Nephron Physiology, 2004, 96, p105-p112.	1.5	24
123	Oxidative Stress – a Link between Endothelial Injury, Coagulation Activation, and Atherosclerosis in Haemodialysis Patients. American Journal of Nephrology, 2004, 24, 154-161.	1.4	66
124	Possible New Role of Monocyte Chemoattractant Protein-1 in Hemodialysis Patients with Cardiovascular Disease. American Journal of Nephrology, 2004, 24, 635-640.	1.4	14
125	Hepatitis intensified oxidative stress, MIP-1Î² and RANTES plasma levels in uraemic patients. Cytokine, 2004, 28, 197-204.	1.4	29
126	Kidney and Liver Kynurenine Pathway Enzymes in Chronic Renal Failure. Advances in Experimental Medicine and Biology, 2003, 527, 409-414.	0.8	22

#	Article	IF	Citations
127	Contribution of quinolinic acid in the development of anemia in renal insufficiency. American Journal of Physiology - Renal Physiology, 2003, 284, F693-F700.	1.3	30
128	Kynurenine Metabolism in Central Nervous System in Experimental Chronic Renal Failure. Advances in Experimental Medicine and Biology, 2003, 527, 177-182.	0.8	12
129	Mechanism of Inhibitory Effect of 3- Hydroxykynurenine on Erythropoiesis in Patients with Renal Insufficiency. Advances in Experimental Medicine and Biology, 2003, 527, 375-380.	0.8	6
130	Antithrombotic Effect of Captopril and Losartan Is Mediated by Angiotensin-(1-7). Hypertension, 2002, 40, 774-779.	1.3	108
131	Endogenous neurotoxine-quinolinic acid is increased in renal allograft recipients. Transplantation Proceedings, 2002, 34, 598-600.	0.3	1
132	Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency. Brain Research Bulletin, 2002, 58, 423-428.	1.4	16
133	Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. International Urology and Nephrology, 2001, 33, 399-404.	0.6	80
134	Importance of Serotonergic Mechanisms in the Thrombotic Complications in Hemodialyzed Patients Treated with Erythropoietin. Nephron, 2000, 84, 305-311.	0.9	21
135	Peripheral Serotonergic System in Hemodialyzed and Peritoneally Dialyzed Patients. Nephron, 2000, 86, 396-397.	0.9	1
136	The involvement of AT2-receptor in the antithrombotic effect of losartan in renal hypertensive rats. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 263-267.	1.0	8
137	The antithrombotic effect of angiotensin-(1â€”7) closely resembles that of losartan. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 268-272.	1.0	31
138	Serotonergic and kynurenic pathways in rats exposed to foot shock. Brain Research Bulletin, 2000, 52, 197-205.	1.4	57
139	Platelet Serotonergic Mechanisms in Patients with Cancer of the Urinary Bladder. Thrombosis Research, 2000, 98, 367-374.	0.8	8
140	Investigations of urinary lead concentration in patients with urinary bladder carcinoma. International Urology and Nephrology, 1999, 31, 661-663.	0.6	2
141	A Potent 5-Hydroxytryptamine Receptor (5-HT2A) Antagonist, DV-7028, Delays Arterial Thrombosis Development in Rats. Thrombosis Research, 1998, 90, 259-270.	0.8	18
142	Losartan Inhibits Experimental Venous Thrombosis in Spontaneously Hypertensive Rats. Thrombosis Research, 1998, 90, 271-278.	0.8	12
143	Hemostasis, Platelet Functions, Serotonin and Serum Lipids during Omega-3 Fatty Acid Treatment in Patients with Glomerulonephritis. Nephron, 1998, 80, 94-96.	0.9	1
144	Vascular and Cardiac Effects of DV-7028, a Selective, 5-HT2-Receptor Antagonist in Rats. Journal of Cardiovascular Pharmacology, 1998, 32, 266-273.	0.8	18

#	Article	IF	Citations
145	Altered Circadian Rhythm of Platelet Aggregation in Hemodialyzed Patients. Nephron, 1997, 77, 365-367.	0.6	2
146	PERIPHERAL SEROTONERGIC SYSTEM IN UREMIA. Thrombosis Research, 1996, 83, 189-194.	0.8	17
147	HEMOSTASIS, PLATELET FUNCTION AND SEROTONIN IN ACUTE AND CHRONIC RENAL FAILURE. Thrombosis Research, 1996, 83, 351-361.	0.8	76
148	Evidence that the 50-kDa substrate of brefeldin A-dependent ADP-ribosylation binds GTP and is modulated by the G-protein beta gamma subunit complex.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7065-7069.	3.3	49
149	Effect of acetaldehyde on the circulatory system in rats. Pharmacological Research, 1992, 25, 113.	3.1	1
150	Blood serotonin is involved in erythropoietin-induced hypertension in uraemic rats. Pharmacological Research, 1992, 25, 111-112.	3.1	0
151	Serotonin is involved in some effects of erythropoietin. Thrombosis Research, 1992, 65, 657-661.	0.8	3
152	Cardiovascular Effects of Acetaldehyde in Pithed Rats. Pharmacology, 1992, 45, 83-89.	0.9	8
153	Influence of Acute and Chronic Ethanol Administration on the Vasopressor Effect of Serotonin in Pithed Rats. Pharmacology, 1990, 41, 91-97.	0.9	0
154	Cardiovascular effects of ethanol in anaesthetized, conscious and pithed rats. Drug and Alcohol Dependence, 1989, 24, 51-56.	1.6	10
155	INFLUENCE OF ACETALDEHYDE ON THE VASOPRESSOR EFFECT OF SEROTONIN IN PITHED RATS. Alcohol and Alcoholism, 0, , .	0.9	0